Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evopep-D insulin
- Development stage
- Preclinical
- Lead developer
- Bhami's Research Laboratory
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
Evopep-D insulin is an oral formulation of human insulin developed by Bhami's Research Laboratory using their proprietary Evopep platform. The Evopep platform is designed to enable the oral delivery of biologics, such as peptides and proteins, which are typically administered via injection due to poor gastrointestinal absorption and enzymatic degradation. In this formulation, human insulin acts as an agonist for the insulin receptor, facilitating glucose uptake and lowering blood sugar levels. Preclinical in-vivo animal studies have demonstrated the oral bioavailability and efficacy of this formulation in managing diabetes.
- Other names
- human insulinEvopep-D (Human Insulin formulation)Evopep-D insulin
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on Evopep-D insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evopep-D insulin.